Prognostic implication and functional role of long noncoding RNA IGF2AS in human non-small cell lung cancer.
Emerging evidence shows that long noncoding RNAs (lncRNAs) play important roles in human cancer. In this work, we examined the expression, prognostic implication and functional mechanisms of a lncRNA, insulin growth factor 2 antisense (IGF2AS) in non-small cell lung cancer (NSCLC). IGF2AS gene expression was examined by qPCR in both in situ NSCLC clinical samples and in vitro NSCLC cell lines. In patients with NSCLC, postoperative overall survival was estimated according to endogenous IGF2AS expression in their cancerous lung tissues. In NSCLC cell lines A549 and H226 cells, IGF2AS was upregulated to examine its effect on cancer proliferation, migration, cisplatin chemoresistance in vitro, and tumorigenicity in vivo. Related signaling pathways, including IGF2, VEGF and bFGF were also examined in IGF2AS upregulated NSCLC cells. IGF2AS is downregulated in both NSCLC human tumors and NSCLC cell lines, as well as in stage III or IV tumors. Downregulated IGF2AS was significantly correlated with NSCLC patients' short overall survival. In NSCLC A549 and H226 cell lines, IGF2AS upregulation had anti-cancer effects by inhibiting cancer cell proliferation, migration and cisplatin chemoresistance in vitro, and explant growth in vivo. Moreover, IGF2AS upregulation markedly reduced oncogenic factors of IGF2, VEGF and bFGF at both mRNA and protein levels. IGF2AS may be a prognostic biomarker for NSCLC. Upregulating IGF2AS may be considered as a novel molecular pathway to fight NSCLC. This article is protected by copyright. All rights reserved.